A platform study to evaluate investigational therapies in chronic hepatitis B infectio

Phase 2

• Conditions: Chronic hepatitis B infection; Infections and Infestations

• Registration Number: ISRCTN29337285
• Lead Sponsor: VIR Biotechnology (United States)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-09-28
• Study Completion: 2023-04-05
• Last Update Posted: 8 April 2024

Recruitment & Eligibility

• Status: Stopped
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Male or female aged 18 years old and over
2. Chronic HBV infection for >/= 6 months
3. A Body Mass Index (BMI) less than 18 kg/m2 or greater than 35 kg/m2

Exclusion Criteria

1. History or current suspicion of malignancy diagnosed or treated within 5 years
2. Any clinically significant medical or psychiatric condition that may interfere with study intervention, assessment, or compliance with the protocol or otherwise makes the participant unsuitable for participation in the study
3. History or evidence of drug or alcohol abuse
4. History of hepatic decompensation

Study & Design

• Study Type: Interventional
• Study Design: Not specified